Related Experiment Video
Updated: Jun 13, 2026
08:28
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Serum efficacy biomarkers for oncology
1Department of Oncology - Pathology, Cancer Center Karolinska, Karolinska Institute, S-171 76 Stockholm, Sweden. stig.linder@ki.se
Biomarkers in Medicine
|May 19, 2010
Summary
Serum efficacy biomarkers show early cancer therapeutic effects, aiding clinical care and drug development. However, biomarker responses may not always align with traditional anatomical assessments of treatment outcomes.
Area of Science:
- Oncology
- Biomarker Research
- Pharmacodynamics
Background:
- Growing interest in serum biomarkers for assessing early cancer therapeutic effects.
- Potential value of efficacy biomarkers in routine clinical care and anticancer drug development.
Purpose of the Study:
- Review the literature on serum efficacy biomarkers.
- Discuss interpretation of biomarker data, focusing on marker specificity.
- Examine congruence between biomarker response and traditional anatomical evaluation.
Main Methods:
- Literature review of serum efficacy biomarkers.
- Analysis of data interpretation and marker specificity.
- Comparative discussion of biomarker versus anatomical assessment.
Main Results:
- Serum efficacy biomarkers offer insights into early therapeutic responses.
- Specificity of different serum markers requires careful consideration.
- Biomarker evaluation may indicate tumor cell death induction, not necessarily clinical outcome.
Conclusions:
- Serum efficacy biomarkers are valuable tools in oncology.
- Interpretation requires attention to specificity and potential discordance with anatomical methods.
- Biomarkers provide unique information on treatment-induced cell death, distinct from clinical outcomes.